These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 2864374)

  • 1. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.
    J Hypertens; 1985 Aug; 3(4):379-92. PubMed ID: 2864374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension.
    Bühler FR; Vesanen K; Watters JT; Bolli P
    Am Heart J; 1988 Jan; 115(1 Pt 2):282-8. PubMed ID: 2892388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial infarctions and cerebrovascular accidents in relation to blood pressure control. The IPPPSH Collaborative Group.
    J Hypertens Suppl; 1985 Dec; 3(3):S513-8. PubMed ID: 2856779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The international prospective primary prevention study in hypertension (IPPPSH): objectives and methods. The IPPPSH Collaborative Group.
    Eur J Clin Pharmacol; 1984; 27(4):379-91. PubMed ID: 6151503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoking, antihypertensive treatment benefit, and comprehensive antihypertensive treatment approach: some thoughts on the results of the International Prospective Primary Prevention Study in Hypertension.
    Bolli P; Bühler FR; McKenzie JK
    J Cardiovasc Pharmacol; 1990; 16 Suppl 7():S77-80. PubMed ID: 1708033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxprenolol in myocardial infarction survivors: brief review of the European Infarction Study results in the light of other beta-blocker post infarction trials.
    Schröder R
    Z Kardiol; 1985; 74 Suppl 6():165-72. PubMed ID: 2869616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study.
    Kjeldsen SE; Hedner T; Syvertsen JO; Lund-Johansen P; Hansson L; Lanke J; Lindholm LH; De Faire U; Dahlöf B; Karlberg BE;
    J Hypertens; 2002 Jun; 20(6):1231-7. PubMed ID: 12023696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.
    Salvetti A; Arzilli F; Pedrinelli R; Beggi P; Motolese M
    Eur J Clin Pharmacol; 1982; 22(3):197-201. PubMed ID: 7049707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
    Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
    JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of long term oxprenolol and chlorthalidone singly and in combination in hypertensive blacks.
    Obel AO
    Jpn Heart J; 1990 Mar; 31(2):183-92. PubMed ID: 2192098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.
    Wilhelmsen L; Berglund G; Elmfeldt D; Fitzsimons T; Holzgreve H; Hosie J; Hörnkvist PE; Pennert K; Tuomilehto J; Wedel H
    J Hypertens; 1987 Oct; 5(5):561-72. PubMed ID: 2892881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
    Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
    J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.
    Ferrara LA; Mancini M; Marotta T; Pasanisi F; Fasano ML
    Eur J Clin Pharmacol; 1986; 29(6):717-9. PubMed ID: 3519237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a sustained-release formulation of oxprenolol and cyclopenthiazide ('Trasidrex') in the management of hypertension: a general practice study.
    Forrest WA
    Curr Med Res Opin; 1980; 6(8):559-63. PubMed ID: 7389387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension.
    Chen JM; Heran BS; Perez MI; Wright JM
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007185. PubMed ID: 20091622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.
    Niskanen L; Hedner T; Hansson L; Lanke J; Niklason A;
    Diabetes Care; 2001 Dec; 24(12):2091-6. PubMed ID: 11723089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive effects of oxprenolol and propranolol.
    Materson BJ; Michael UF; Oster JR; Perez-Stable EC
    Clin Pharmacol Ther; 1976 Aug; 20(2):142-51. PubMed ID: 780037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive effectiveness of oxprenolol administered twice daily.
    Materson BJ; Oster JR; Michael UF; Perez-Stable EC
    Clin Pharmacol Ther; 1976 Mar; 19(3):325-32. PubMed ID: 770050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.